Delhi HC to Rule on Novo Nordisk’s Bid to Block Indian Semaglutide Exports
The Delhi High Court has reserved its order on a plea by Novo Nordisk seeking an injunction against Dr Reddy’s Laboratories to prevent the export of generic semaglutide. The Danish pharmaceutical giant alleges patent infringement on the key ingredient of its blockbuster drugs Wegovy and Ozempic.
Key Takeaways
- Novo Nordisk has sued Dr Reddy’s and Sun Pharma in Delhi HC for alleged patent infringement on semaglutide.
- The court will decide on an interim injunction to block the launch of generic versions in India.
- The case highlights the multi-billion dollar stakes in the global GLP-1 drug market.
The Patent Dispute
Novo Nordisk filed lawsuits against two major Indian drugmakers, Dr Reddy’s Laboratories and Sun Pharmaceutical Industries. The company claims the firms have infringed its patents covering semaglutide, its manufacturing process, and its medical use for obesity and diabetes.
The cases, scheduled for hearing on October 2, seek to prevent the Indian companies from launching their own versions of the drug in the Indian market.
What is Semaglutide?
Semaglutide is a GLP-1 receptor agonist that regulates blood sugar and suppresses appetite. It has gained worldwide popularity for weight management, causing supply shortages in several countries.
Novo Nordisk holds multiple Indian patents for the compound, with the earliest expiring in 2026. The company is pursuing interim injunctions, damages, and a permanent ban on generic launches.
Indian Firms Respond
Both Dr Reddy’s and Sun Pharma confirmed receiving legal notices and stated they are reviewing the claims. The companies have expressed their intention to defend their positions in court.
Broader Market Implications
This legal battle underscores the high-value competition in the global GLP-1 drug market, projected to exceed $100 billion annually. It represents a classic clash between innovator firms protecting intellectual property and generic manufacturers aiming to provide affordable alternatives.
In India, where diabetes and obesity are significant health challenges, cheaper generic semaglutide could dramatically improve treatment access for millions.
